Trial
NCT03904069
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
—
Condition
Relapsed/Refractory Acute Myeloid Leukemia
Intervention
AMG 553
Why stopped
Following a recent cellular therapy strategy assessment, Amgen has decided to cancel study 20180091.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-12